MoonLake Immunotherapeutics MLTX Other Nonoperating Income
Other Nonoperating Income at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's other nonoperating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's other nonoperating income?
- MoonLake Immunotherapeutics (MLTX) reported other nonoperating income of $3.21M in Q1 2026.
- How has MoonLake Immunotherapeutics's other nonoperating income changed year-over-year?
- MoonLake Immunotherapeutics's other nonoperating income decreased by 54.8% year-over-year, from $7.1M to $3.21M.
- What is the long-term trend for MoonLake Immunotherapeutics's other nonoperating income?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's other nonoperating income has grown at a 235.6% compound annual growth rate (CAGR), from $591.73K to $22.37M.
- What does other nonoperating income mean?
- This metric represents income or expenses generated from activities outside of the company's core clinical-stage biotechnology operations. It typically includes items such as interest income, foreign exchange gains or losses, and other miscellaneous financial activities not directly related to drug development. Monitoring this helps investors distinguish between core operational performance and peripheral financial gains or costs.